CL2017000625A1 - Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos - Google Patents
Composiciones de glicoconjugado inmunogénico/terapéutico y sus usosInfo
- Publication number
- CL2017000625A1 CL2017000625A1 CL2017000625A CL2017000625A CL2017000625A1 CL 2017000625 A1 CL2017000625 A1 CL 2017000625A1 CL 2017000625 A CL2017000625 A CL 2017000625A CL 2017000625 A CL2017000625 A CL 2017000625A CL 2017000625 A1 CL2017000625 A1 CL 2017000625A1
- Authority
- CL
- Chile
- Prior art keywords
- therapeutic
- disease
- klh
- obi
- severity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001173—Globo-H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<p>LA PRESENTE DESCRIPCIÓN INCLUYE COMPOSICIONES INMUNOGÉNICAS/TERAPÉUTICAS QUE INCLUYEN GLICOCONJUGADOS GLOBO H-KLH (OBI-822) Y/O ADYUVANTES TERAPÉUTICOS (OBI-821/OBI-834) ASÍ COMO TAMBIÉN, MÉTODOS PARA PREPARARLOS Y UTILIZARLOS PARA TRATAR ENFERMEDADES PROLIFERATIVAS COMO EL CÁNCER. ESTOS CONJUGADOS TERAPÉUTICOS INCLUYEN UN ANTÍGENO LIGADO A UN VEHÍCULO. EN PARTICULAR, LOS CONJUGADOS TERAPÉUTICOS INCLUYEN UNA PORCIÓN GLOBO H Y UNA PORCIÓN KLH Y/O UNA SUBUNIDAD DE PORCIÓN KLH DERIVADA OPCIONALMENTE LIGADA MEDIANTE UN LIGANTE. LAS COMPOSICIONES TERAPÉUTICAS ESTÁN EN PARTE CONCEBIDAS PARA ACTUAR COMO VACUNAS CONTRA EL CÁNCER PARA ESTIMULAR LA CAPACIDAD NATURAL QUE TIENE EL CUERPO DE PROTEGERSE A SÍ MISMO, A TRAVÉS DEL SISTEMA INMUNOLÓGICO, DE LOS PELIGROS IMPUESTOS POR LAS CÉLULAS DAÑADAS O ANORMALES COMO LAS CÉLULAS CANCERÍGENAS. LA RESPUESTA INMUNOLÓGICA EJEMPLAR PUEDE SER CARACTERIZADA MEDIANTE LA REDUCCIÓN DE LA SEVERIDAD DE LA ENFERMEDAD, INCLUSO PERO SIN LIMITARSE A LA PREVENCIÓN DE LA ENFERMEDAD, INCLUSO EN EL INICIO DE LA ENFERMEDAD, DISMINUCIÓN DE LA SEVERIDAD DE LOS SÍNTOMAS, MORBILIDAD DISMINUIDA Y MORTALIDAD RETARDADA.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050567P | 2014-09-15 | 2014-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000625A1 true CL2017000625A1 (es) | 2018-02-02 |
Family
ID=55533765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000625A CL2017000625A1 (es) | 2014-09-15 | 2017-03-14 | Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160339089A1 (es) |
| EP (1) | EP3193919B1 (es) |
| JP (1) | JP6774941B2 (es) |
| KR (2) | KR102679516B1 (es) |
| CN (1) | CN107427564A (es) |
| AR (1) | AR101871A1 (es) |
| AU (1) | AU2015317889B2 (es) |
| BR (1) | BR112017005120B1 (es) |
| CA (1) | CA2961522A1 (es) |
| CL (1) | CL2017000625A1 (es) |
| ES (1) | ES2797747T3 (es) |
| IL (1) | IL251120B (es) |
| MY (1) | MY188880A (es) |
| PH (1) | PH12017500478B1 (es) |
| RU (1) | RU2720295C2 (es) |
| SG (1) | SG11201702037SA (es) |
| TW (1) | TWI726850B (es) |
| WO (1) | WO2016044326A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015159118A2 (en) | 2013-09-17 | 2015-10-22 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
| US10935544B2 (en) | 2015-09-04 | 2021-03-02 | Obi Pharma, Inc. | Glycan arrays and method of use |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| WO2017172990A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| WO2017185089A2 (en) * | 2016-04-22 | 2017-10-26 | Obi Pharma, Inc. | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
| BR112019001656A2 (pt) | 2016-07-27 | 2019-05-28 | Obi Pharma Inc | composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo |
| EP3491026A4 (en) | 2016-07-29 | 2020-07-29 | OBI Pharma, Inc. | HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| CN110290800A (zh) | 2016-11-21 | 2019-09-27 | 台湾浩鼎生技股份有限公司 | 缀合生物分子、医药组合物及方法 |
| CN112513635B (zh) * | 2018-05-11 | 2024-04-16 | 台湾浩鼎生技股份有限公司 | 预测人体免疫反应的方法 |
| TWI853822B (zh) | 2018-06-27 | 2024-09-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544952B1 (en) * | 1994-03-15 | 2003-04-08 | Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
| US7824687B2 (en) * | 1999-08-20 | 2010-11-02 | Sloan-Kettering Institute For Cancer Research | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof |
| US7854934B2 (en) * | 1999-08-20 | 2010-12-21 | Sloan-Kettering Institute For Cancer Research | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
| JP2005526692A (ja) * | 2001-08-14 | 2005-09-08 | ビオミラ，インコーポレーテッド | 炭水化物ハプテンの免疫原共役体および凝集タンパク質キャリヤ |
| US20090317411A1 (en) * | 2008-06-16 | 2009-12-24 | Academia Sinica | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| CN105535955B (zh) * | 2009-06-16 | 2019-04-23 | 中央研究院 | Globo h及含新颖糖脂质佐剂的相关抗癌疫苗 |
| EP2500035A1 (en) * | 2011-03-15 | 2012-09-19 | Icon Genetics GmbH | Pharmaceutical formulation containing immunglobulin |
| TWI572356B (zh) * | 2013-01-04 | 2017-03-01 | 台灣浩鼎生技股份有限公司 | 具有較高碳水化合物抗原密度之疫苗及新穎皂素佐劑 |
| WO2015159118A2 (en) * | 2013-09-17 | 2015-10-22 | Obi Pharma, Inc. | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
-
2015
- 2015-09-15 WO PCT/US2015/050270 patent/WO2016044326A1/en active Application Filing
- 2015-09-15 CN CN201580062962.2A patent/CN107427564A/zh active Pending
- 2015-09-15 PH PH1/2017/500478A patent/PH12017500478B1/en unknown
- 2015-09-15 TW TW104130500A patent/TWI726850B/zh active
- 2015-09-15 EP EP15842660.1A patent/EP3193919B1/en active Active
- 2015-09-15 US US14/855,260 patent/US20160339089A1/en active Pending
- 2015-09-15 AU AU2015317889A patent/AU2015317889B2/en active Active
- 2015-09-15 SG SG11201702037SA patent/SG11201702037SA/en unknown
- 2015-09-15 ES ES15842660T patent/ES2797747T3/es active Active
- 2015-09-15 KR KR1020177009879A patent/KR102679516B1/ko active Active
- 2015-09-15 KR KR1020237023433A patent/KR102702705B1/ko active Active
- 2015-09-15 RU RU2017112982A patent/RU2720295C2/ru active
- 2015-09-15 JP JP2017514552A patent/JP6774941B2/ja active Active
- 2015-09-15 AR ARP150102941A patent/AR101871A1/es not_active Application Discontinuation
- 2015-09-15 CA CA2961522A patent/CA2961522A1/en active Pending
- 2015-09-15 MY MYPI2017000385A patent/MY188880A/en unknown
- 2015-09-15 BR BR112017005120-6A patent/BR112017005120B1/pt active IP Right Grant
-
2017
- 2017-03-13 IL IL251120A patent/IL251120B/en active IP Right Grant
- 2017-03-14 CL CL2017000625A patent/CL2017000625A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ730480A (en) | 2024-09-27 |
| JP2017532310A (ja) | 2017-11-02 |
| IL251120A0 (en) | 2017-04-30 |
| BR112017005120A2 (pt) | 2018-01-23 |
| JP6774941B2 (ja) | 2020-10-28 |
| CN107427564A (zh) | 2017-12-01 |
| RU2017112982A (ru) | 2018-10-17 |
| AU2015317889A1 (en) | 2017-04-13 |
| EP3193919A4 (en) | 2018-04-18 |
| AU2015317889B2 (en) | 2021-06-03 |
| PH12017500478A1 (en) | 2017-07-10 |
| PH12017500478B1 (en) | 2022-06-22 |
| KR20230109783A (ko) | 2023-07-20 |
| KR102702705B1 (ko) | 2024-09-04 |
| MY188880A (en) | 2022-01-12 |
| KR20170090405A (ko) | 2017-08-07 |
| SG11201702037SA (en) | 2017-04-27 |
| AR101871A1 (es) | 2017-01-18 |
| CA2961522A1 (en) | 2016-03-24 |
| KR102679516B1 (ko) | 2024-07-02 |
| ES2797747T3 (es) | 2020-12-03 |
| TWI726850B (zh) | 2021-05-11 |
| TW201628646A (zh) | 2016-08-16 |
| BR112017005120B1 (pt) | 2021-01-05 |
| US20160339089A1 (en) | 2016-11-24 |
| IL251120B (en) | 2021-05-31 |
| RU2017112982A3 (es) | 2019-04-24 |
| EP3193919B1 (en) | 2020-04-08 |
| RU2720295C2 (ru) | 2020-04-28 |
| WO2016044326A1 (en) | 2016-03-24 |
| WO2016044326A9 (en) | 2017-05-11 |
| EP3193919A1 (en) | 2017-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000625A1 (es) | Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos | |
| AR097661A1 (es) | Composiciones de una vacuna de carbohidratos para inducir respuestas inmunológicas y sus usos en el tratamiento del cáncer | |
| WO2015168379A3 (en) | Combination vaccine devices and methods of killing cancer cells | |
| MX2023002858A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
| CL2017000310A1 (es) | Anticuerpos anti tigit | |
| AR104664A1 (es) | Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6) | |
| CO2017004932A2 (es) | Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva | |
| MX2017004897A (es) | Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer. | |
| MX393612B (es) | Vacuna contra viruela para tratamiento del cancer. | |
| MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
| CL2017001135A1 (es) | Anticuerpos mejorados contra il-6 | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| MX2023001540A (es) | Vacunas contra el cancer y metodos de tratamiento que las utilizan. | |
| GT201700194A (es) | Formulación de combinación de tesofensina y betabloqueante | |
| NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
| CL2016002469A1 (es) | Sulfamidasa modificada y su producción | |
| UY36617A (es) | Proteínas de fusión inmunogénicas para el tratamiento del cáncer | |
| ES2503516R1 (es) | Complejo inmunogénico para vacunación y método de obtención | |
| BR112017002206A2 (pt) | peptídeo derivado de koc1 e vacina incluindo o mesmo | |
| NI201800105A (es) | Anticuerpos, composiciones y antígenos de chaga, métodos y usos de los mismos. | |
| UY36860A (es) | Vacunas recombinantes contra el calicivirus felino (fcv) y sus usos | |
| BR112017002193A2 (pt) | peptídeo derivado de urlc10 e vacina contendo o mesmo | |
| AR093687A2 (es) | Vacunas | |
| CL2018002004A1 (es) | Conjugado amiloide y usos y procedimientos del mismo |